Barclays Portfolio holdings
Barclays is a British universal bank whose roots go back to 1690, when the Quakers John Freame and Thomas Gould started a goldsmith banking business in London. The Barclays name came into the business in 1736, when James Barclay, son-in-law of founder John Freame, became a partner. Barclays launched the UK's first credit card, Barclaycard, in 1966, and in 1967 put the world's first cash machine in a branch in Enfield. In 2008 Barclays bought the North American operations of Lehman Brothers, and in 2009 it sold its Barclays Global Investors unit, home of the iShares ETFs, to BlackRock. It runs five divisions: UK consumer banking, UK corporate banking, private banking and wealth management, an investment bank and a US consumer bank.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$17.5B |
| 2 |
NVIDIA
NVDA
|
+$2.7B |
| 3 |
Intel
INTC
|
+$1.98B |
| 4 |
Broadcom
AVGO
|
+$1.46B |
| 5 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$1.11B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$35.8B |
| 2 |
Apple
AAPL
|
+$1.83B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$913M |
| 4 |
Microsoft
MSFT
|
+$856M |
| 5 |
Bank of America
BAC
|
+$792M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 49.47% |
| 2 | Technology | 19.84% |
| 3 | Consumer Discretionary | 7.61% |
| 4 | Financials | 5.61% |
| 5 | Communication Services | 3.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4276
Commerce.com Inc Series 1
CMRC
$304M
| $93.2K | ﹤0.01% |
29,491
+18,429
| +167% | +$52.4K |
2022 Q1
18 quarters
|
|
4277
Quantum-Si Incorporated
QSI
$279M
| $93.1K | ﹤0.01% |
86,974
-118,716
| -58% | -$95.2K |
2022 Q1
18 quarters
|
|
4278
Lexeo Therapeutics
LXEO
$258M
| $92.9K | ﹤0.01% |
27,482
+11,225
| +69% | +$50.8K |
2023 Q4
11 quarters
|
|
4279
Virginia National Bankshares
VABK
$292M
| $92.5K | ﹤0.01% |
1,940
+1,278
| +193% | +$59.5K |
2023 Q2
13 quarters
|
|
4280
PUT
Entegris
ENTG
$23.4B
| $92.4K | ﹤0.01% |
600
| – | – |
2026 Q2
1 quarter
|
|
4281
Eledon Pharmaceuticals
ELDN
$220M
| $92.2K | ﹤0.01% |
36,445
+24,556
| +207% | +$82.5K |
2024 Q4
7 quarters
|
|
4282
Surrozen
SRZN
$376M
| $92.1K | ﹤0.01% |
2,863
+1,096
| +62% | +$24.7K |
2026 Q1
2 quarters
|
|
4283
SpyGlass Pharma
SGP
$1.17B
| $92K | ﹤0.01% |
3,540
+1,331
| +60% | +$32.8K |
2026 Q1
2 quarters
|
|
4284
Stevanato
STVN
$3.82B
| $91.5K | ﹤0.01% |
4,360
-3,032
| -41% | -$62.7K |
2026 Q1
2 quarters
|
|
4285
OneWater Marine
ONEW
$166M
| $91.5K | ﹤0.01% |
9,598
+3,038
| +46% | +$35.2K |
2022 Q1
18 quarters
|
|
4286
Suzano
SUZ
$11.9B
| $91.3K | ﹤0.01% |
10,650
| – | – |
2024 Q2
9 quarters
|
|
4287
GCT Semiconductor Holding
GCTS
$143M
| $90.8K | ﹤0.01% |
42,808
+35,718
| +504% | +$74.7K |
2026 Q2
1 quarter
|
|
4288
Acme United Corp
ACU
$267M
| $90.4K | ﹤0.01% |
1,425
+840
| +144% | +$48.2K |
2024 Q3
8 quarters
|
|
4289
PUT
Fiserv Inc
FISV
$33.9B
| $90.4K | ﹤0.01% |
2,000
-1,328,500
| -100% | -$68M |
2026 Q2
1 quarter
|
|
4290
Chicago Atlantic Real Estate Finance
REFI
$229M
| $90.3K | ﹤0.01% |
9,012
+6,197
| +220% | +$65.3K |
2022 Q1
18 quarters
|
|
4291
Peoples Bancorp of North Carolina
PEBK
$230M
| $89.9K | ﹤0.01% |
2,098
+1,099
| +110% | +$47.7K |
2023 Q3
12 quarters
|
|
4292
Pure Cycle
PCYO
$264M
| $89.8K | ﹤0.01% |
8,137
+5,130
| +171% | +$56.4K |
2017 Q2
37 quarters
|
|
4293
Spok Holdings
SPOK
$247M
| $89.8K | ﹤0.01% |
8,561
+2,052
| +32% | +$21.9K |
2013 Q2
53 quarters
|
|
4294
Context Therapeutics
CNTX
$18.7M
| $89.5K | ﹤0.01% |
297,854
+270,350
| +983% | +$133K |
2026 Q2
1 quarter
|
|
4295
TON Strategy Co
TONX
$210M
| $89.2K | ﹤0.01% |
23,607
+23,228
| +6,129% | +$75K |
2026 Q1
2 quarters
|
|
4296
Century Therapeutics
IPSC
$310M
| $89.2K | ﹤0.01% |
52,168
+27,468
| +111% | +$56.3K |
2022 Q1
18 quarters
|
|
4297
Funko
FNKO
$403M
| $89.2K | ﹤0.01% |
16,488
+9,278
| +129% | +$54K |
2017 Q4
35 quarters
|
|
4298
Crexendo
CXDO
$169M
| $89K | ﹤0.01% |
15,142
+4,404
| +41% | +$29.2K |
2024 Q3
8 quarters
|
|
4299
Aurora Cannabis
ACB
$332M
| $88.9K | ﹤0.01% |
22,801
+800
| +4% | +$2.72K |
2022 Q1
18 quarters
|
|
4300
OPAL Fuels
OPAL
$43.3M
| $88.9K | ﹤0.01% |
50,789
+47,118
| +1,284% | +$100K |
2025 Q2
5 quarters
|
|
Similar funds
Barclays's Q3 2026 Portfolio in Review
As of Q3 2026, Barclays held 5,855 positions worth $500B, down 4% from $521B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Barclays withdrew a net $19B in Q3 2026, closing 474 positions and reducing 1,494 holdings. Its most notable exit was ExxonMobil, an estimated $761M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, down from 55% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Barclays opened a new position in iShares Broad USD High Yield Corporate Bond ETF worth $199M.
- Barclays's largest Q3 2026 buy was iShares Broad USD High Yield Corporate Bond ETF: 5,582,517 shares worth $199M.
- Barclays added most to Tesla in Q3 2026, an estimated $17.5B increase.
- Barclays's biggest Q3 2026 reduction was iShares MSCI Emerging Markets ETF, cutting an estimated $35.8B.
- Barclays fully exited ExxonMobil in Q3 2026, selling an estimated $761M.
- Barclays's ten largest holdings make up 40% of its $500B portfolio in Q3 2026.
- Barclays opened 525 new positions and closed 474 in Q3 2026.
- Barclays's portfolio value fell 4% quarter-over-quarter to $500B.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.